Compare Abeona Therapeutics Inc (ABEO) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Lamb Weston Holdings Inc — how do they compare? Abeona Therapeutics Inc trades at $7.34 (market cap $421.19M), while Lamb Weston Holdings Inc trades at $52.51 (market cap $7.23B). The key difference: Lamb Weston Holdings Inc is far larger — about 17.2× Abeona Therapeutics Inc's market cap, and Lamb Weston Holdings Inc pays a 2.89% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | LW | |
|---|---|---|
Market Cap | $421.19M | $7.23B |
Sector | Health | Consumer Staples |
52-Week High | $7.45 | $66.57 |
52-Week Low | $4.17 | $38.48 |
Enterprise Value | $276.10M | $11.10B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
Lamb Weston (LW) trades at $51.81, down 0.88% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 16.28% ROE and a 4.39% net margin, supported by positive cash flow from operations of $868.3M in 2025. Recent news highlights Q4 2026 results exceeding expectations and a declared $0.38 dividend.
Outlook remains positive with a consensus price target of $53.86, though risks include margin pressure from cost inflation and international headwinds. The stock offers a solid dividend yield and growth potential from operational improvements, but investors should monitor debt levels and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
